Movement Disorders at Biogen

Tien Dam, M.D., Head of Movement Disorders
Carole Ho, M.D., Chief Medical Officer & Head of Development, Denali Therapeutics

R&D Day
September 21, 2021
Forward-looking statements

This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our and our collaboration partners’ products and investigational therapies; the anticipated benefits and potential of investments, collaborations, and business development activities; and our future financial and operating results. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

These statements involve risks and uncertainties that could result in actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our control; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; risks relating to technology failures or breaches; risks relating to management and key personnel changes, including attracting and retaining key personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; problems with our manufacturing processes; fluctuations in our effective tax rate; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business, results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission (SEC).

These statements are based on our current beliefs and expectations and speak only as of the date of this presentation. We do not undertake any obligation to publicly update any forward-looking statements.
Biogen has one of the leading movement disorders pipelines

<table>
<thead>
<tr>
<th>Program Details</th>
<th>Pre-R2D</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB124 (GABA(_A) modulator SM)*</td>
<td></td>
<td></td>
<td></td>
<td>Purple</td>
</tr>
<tr>
<td>Essential Tremor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB122 (LRRK2 SM)**</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB094 (LRRK2 ASO)#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB118 (CK1 SM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BIIB101 ((\alpha)-synuclein ASO)#</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multiple System Atrophy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Undisclosed programs (multiple modalities)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Undisclosed program</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinocerebellar Ataxia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Undisclosed programs (multiple modalities)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*collaboration with Sage Therapeutics
**collaboration with Denali Therapeutics
#collaboration with Ionis Pharmaceuticals

ASO = antisense oligonucleotide; CK1 = casein kinase 1; GABA\(_A\) = gamma-aminobutyric acid type A; LRRK2 = leucine rich repeat kinase 2; PAM = positive allosteric modulator; SM = small molecule
Highlights on Movement Disorders Portfolio

01 Movement Disorders Pipeline and Strategy
Multi-modality, multi-target approach

02 Advances in Therapies for Parkinson’s Disease
BIIB122 (DNL 151) – LRRK2 Kinase Inhibitor
(in collaboration with Denali Therapeutics)

BIIB094 – LRRK2 ASO
(in collaboration with Ionis Pharmaceuticals)

BIIB118 – CK1 Inhibitor

03 Novel Approach to Essential Tremor
BIIB124 (SAGE-324) – GABA<sub>A</sub> PAM
(in collaboration with Sage Therapeutics)
Biogen’s R&D strategy in movement disorders

Leverage scientific, clinical, and commercial synergies – and Biogen’s multi-modality expertise – to address patient needs

<table>
<thead>
<tr>
<th>Parkinson’s disease: Slow progression and address major untreated symptoms</th>
<th>Atypical Parkinsonism: Target proteins that form aggregates in severe, rare Parkinsonisms</th>
<th>Genetically defined movement disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Despite dopamine replacement therapies, there is no disease-modifying therapy for Parkinson’s disease</td>
<td>• Progressive supranuclear palsy (PSP) and Multiple system atrophy (MSA) are rapidly progressing, fatal conditions</td>
<td>• Mitigate risk by targeting genetic adjacencies</td>
</tr>
<tr>
<td>• Major clinical needs (e.g., cognitive deficits) remain untreated</td>
<td>• Tau and α-synuclein compounds have potential for PSP and MSA</td>
<td></td>
</tr>
</tbody>
</table>
Disease modifying therapies are a critical unmet medical need in Parkinson’s disease

- Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease \(^1,^2\)
- In 2020, approximately 10 million individuals with PD worldwide \(^3\)
- Misfolded and aggregated forms of α-synuclein form intracellular proteinaceous inclusions called Lewy bodies and Lewy neurites, which, along with the loss of dopaminergic neurons in the substantia nigra, form the pathological characteristics of PD \(^4\)
- Classic motor symptoms of PD include bradykinesia, rigidity, rest tremor, and postural instability \(^5,^6\)
- The average age of onset of motor manifestations is in the late 50s, with a broad range from age < 50 to > 80 years. \(^2\)
- Treatment with dopamine replacement therapies (e.g., levodopa / dopamine agonists, MAO-B inhibitors) temporarily improves motor symptoms

---


MAO-B inhibitors = monoamine oxidase B inhibitors
Biogen’s multi-prong approach to Parkinson’s disease targeting α-synuclein and LRRK2

SCNA = alpha synuclein gene
BIIB122 (DNL151)

A selective, small molecule central nervous system-penetrant LRRK2 kinase inhibitor under investigation for the treatment of Parkinson’s disease

In collaboration with Denali Therapeutics – Carole Ho, MD, Chief Medical Officer & Head of Development

The statements included in this presentation are Denali’s and do not necessarily reflect those of Biogen or any other party.
Role of LRKK2 in the pathophysiology of Parkinson’s disease

Lysosomal dysfunction plays a central role in the pathology of Parkinson’s disease\(^1,2\)

LRKK2 activity is increased in Parkinson’s disease and negatively regulates lysosomal function\(^2,3\)

LRKK2 inhibition rescues lysosomal function and normalizes protein processing\(^4-7\)

---


\(\text{aSyn} = \alpha\text{synuclein}; \ GBA = \text{glucocerebrosidase gene}\)
Rationale for LRRK2 as a therapeutic target

Genetic studies highlight multiple lysosomal function related genes in Parkinson's disease.
Lysosomal dysfunction is central to the pathogenesis of Parkinson's disease.

Human LRRK2 LoF variants do not have functional consequences.
Human LRRK2 LoF variants support safety of targeting LRRK2.

LoF = loss-of-function
LRRK2 Inhibition may be therapeutically beneficial in LRRK2 mutation carriers and idiopathic Parkinson’s disease

LRRK2 activation is established in familial Parkinson’s with kinase activating mutations; LRRK2 activation may also drive idiopathic disease

LRRK2 inhibitors may have therapeutic potential to treat LRRK2 and other drivers of lysosomal dysfunction

LRRK2 Mutant Cell

\[
\text{Lysosomal Degradation (Fold Change over WT Vehicle)}
\]

GBA Mutant Cell

\[
\text{Lysosomal Degradation (Fold Change over Vehicle Control)}
\]
BIIB122/DNL151 Phase 1 and Phase 1b Study Design

**Phase 1 study (DNLI-C-0001)**
Single-ascending dose (SAD) and 10-day, 14-day, and 28-day multiple-ascending dose (MAD) parts in healthy volunteers (HVs)

- **PART A, C**
  - Single Dose
  - Part A: young HV (n = 40)
  - Part C: elderly HV (n = 8)
  - Doses: 10-300 mg
  - N=56 total (7 cohorts)
    - (6:2, active: PBO)

- **PART B, D**
  - Multiple Doses
  - QD Dosing
  - Part B: 10-day (n = 63)
  - Part D: 28 day (n = 17)
  - Doses: 15-300 mg QD
  - N=97 total (9 cohorts)
    - Part B: (8:2, active: PBO)
    - Part D: (12:4, active: PBO)

- **PART E**
  - Multiple Doses
  - BID Dosing
  - Part E: 14-day (n – 31)
  - Doses: 150-400mg BID
  - N=31 total (3 cohorts)
    - (8:2, active: PBO)

**Primary Endpoints**
- Adverse events (AEs) and serious adverse events (SAEs), clinically significant changes in laboratory tests, ECGs, pulmonary function, physical and neurological examinations
- Plasma PK

**Secondary Endpoints**
- Cerebrospinal fluid (CSF) PK
- Pharmacodynamic measure of pS935 in whole blood (change from Baseline to steady state)

**Phase 1b trial (DNLI-C-0003)**
Parallel-group design of BIIB122/DNL151 in patients with PD

- **PART 1**
  - Doses: 80 mg or PBO QD
  - N=8
    - (1:1, 80 mg: PBO)

- **PART 2**
  - Doses: 130 mg, 80 mg or PBO QD
  - N=17 total
    - (2:1:1, 130 mg: 80 mg :PBO)

- **PART 3**
  - Doses: 300 mg or PBO QD
  - N=11 total
    - (4:1, 300 mg: PBO)

**Primary Endpoints**
- AEs and SAEs, clinically significant changes in laboratory tests, ECGs, pulmonary function, physical and neurological examinations

**Secondary Endpoints**
- Cerebrospinal fluid (CSF) PK
- Pharmacodynamic measure of pS935 in whole blood (change from Baseline to steady state)
BIIB122/DNL151 is brain penetrant in humans and non-human primate (NHP) and inhibits brain LRRK2 kinase activity

**Kinase Inhibition in Brain & PBMC Relative to Unbound DNL151 Concentration (NHP)**

<table>
<thead>
<tr>
<th>CSF: Unbound Plasma Ratio</th>
<th>Parkinson’s Patients (Day 28)</th>
<th>NHP (Day 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CSF: Plasma PK Ratio (Steady State)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.0</td>
<td>0.5</td>
<td>1.0</td>
</tr>
</tbody>
</table>

- **BIIB122/DNL151** demonstrates CSF penetration with steady-state mean CSF to unbound plasma ratio of ~ 1.0 in healthy volunteers and Parkinson’s patients.
- Kinase inhibition in cynomolgus in peripheral blood mononuclear cells is well correlated with brain.

---

CSF = cerebrospinal fluid; PBMC = peripheral blood mononuclear cells; pS935 = phosphorylation of Serine 935 of LRRK2; PK = pharmacokinetics
Phase 1 healthy volunteer data supports target engagement

**Target Engagement**

**QD Cohorts**

BIIB122/DNL151 achieved LRRK2 target engagement across broad dose ranges and was generally well tolerated in healthy volunteers.

BID = twice daily; BL = baseline; IQR = interquartile range; QD = once daily
Phase 1 healthy volunteer data supports effects on pathway biology and lysosomal function

**Pathway Engagement**
Reduction of pRAB10 (PBMCs) QD

**Pathway Engagement**
Reduction of pRAB10 (PBMCs) BID

**Lysosomal Function**
Reduction of BMP (Urine)

BIIB122/DNL151 achieved downstream biological pathway engagement at doses above 70 mg QD and modulated lysosomal function at doses of 225 mg QD and higher.

BMP = bis(monoacylglycerol); pRAB10 = phosphorylation of RAB10
BIIB122/DNL151 achieved LRRK2 target engagement and downstream biological pathway engagement, and was generally well tolerated in healthy volunteers and patients with Parkinson’s disease.
BIIB122 advancing to late-stage development

ENGAGING PATIENT NETWORKS

- Parkinson's Foundation
- PD GENERation: Mapping the Future of Parkinson's Disease
- The MIND Initiative: The Molecular Integration in Neurological Diagnosis
- Perelman School of Medicine, University of Pennsylvania
- FOX INSIGHT: Your Experience Fueling Research
- PDBP: National Institute of Neurological Disorders and Stroke
- ENGAGE PARKINSON'S
- CENTOGENE: The Rare Disease Company
- Rostock International Parkinson's Disease Study (ROPAD)
- Luebeck International Parkinson's Disease Project (LIPAD)
- Families in research for Parkinson's
Novel potential treatment of Parkinson’s disease

- Mutations in LRRK2 are one of the most common genetic risk factors in Parkinson’s and inhibiting LRRK2 has broad potential in Parkinson’s Disease
- BIIB122/DNL151 is an investigational, selective, central nervous system–penetrant LRRK2 kinase inhibitor
- Data generated by the Phase 1 (healthy volunteer) and Phase 1b (patient) studies support goal to improve lysosomal function and slow progression of disease
- Plan to advance BIIB122/DNL151 into late-stage development
BIIB094

A selective, ASO targeting mRNA of LRRK2 under investigation for the treatment Parkinson’s disease

In collaboration with Ionis Pharmaceuticals
LRRK2 ASO reduces α-syn pathology in mouse model and reduces LRRK2 mRNA and protein in NHP after IT delivery

ASO Reduces mRNA/Protein by ~50% and Attenuates α-Syn Pathology & Neuronal Loss in Mouse PFF Model

ASO Reduces LRRK2 mRNA & protein in multiple brain regions in NHP

IT = intrathecal; mRNA = messenger RNA; NHP = non-human primate; PFF = preformed fibril; SN= substantia nigra

Tracy Cole, Patrick Trapa, Melissa Berman, Omar Mabrouk – Ionis / Biogen
## BIIB094 clinical development

### Ongoing phase 1 SAD/MAD study

A study to evaluate the safety, tolerability, and pharmacokinetics of BIIB094 in adults with Parkinson’s disease

<table>
<thead>
<tr>
<th>Key Endpoints</th>
<th>Population (planned n=82)</th>
<th>Design</th>
</tr>
</thead>
</table>
| • Primary: Incidence of adverse events and serious adverse events  
  • Secondary: CSF and serum concentrations of LRRK2 ASO (Cmax, AUC, Tmax, T½)  
  • Exploratory:  
    • Clinical scales including MDS-UPDRS  
    • CSF levels of LRRK2 Protein | • PD diagnosed within the last 7 years  
  • Treatment naïve or stable symptomatic therapy | • SAD: 6 ascending dose cohorts (randomized to BIIB094 or placebo) – single intrathecal (IT) dose  
  • MAD: 5 ascending dose cohorts (randomized to BIIB094 or placebo) – single monthly IT dose for 4 consecutive months |

AUC = area under the curve; Cmax = maximum concentration; MAD = multiple ascending dose; MDS-UPDRS = Movement Disorders Society sponsored revision of the Unified Parkinson’s Disease Rating Scale; SAD = single ascending dose; Tmax = time at Cmax; T½ = half life
BIIB118

A selective, small-molecule, central nervous system-penetrant, dual inhibitor of CK1δ and CK1ε under investigation for the treatment of Circadian rhythm disruptions in Parkinson’s disease.
BIIB118 could compensate for decreased circadian amplitude and improve sleep and other non-motor symptoms

- Sleep-wake disturbances are common non-motor symptoms of Parkinson’s disease
  - Sleep maintenance, insomnia, and sleep fragmentation are the most prevalent with 37-58% of Parkinson’s patients reporting insomnia
  - Sleep disturbances are associated with fatigue, depressive symptoms, worse cognition, and overall decreased quality of life
  - Dampening of multiple physiological circadian rhythms, particularly a significant decrease in 24-hour melatonin secretion, have been observed in Parkinson’s disease vs age-matched controls
  - BIIB118 is a circadian agent proposed to minimize circadian rhythm disruptions

1. Chaudhuri KR et al. Mov Disord. 2010
4. Duncan GW et al. Mov Disord. 2014

Blunted physiological (i.e., melatonin) and molecular (i.e., circadian genes, not shown) circadian rhythms in PD

Figure. Plasma Melatonin Concentration During 24-Hour Modified Constant Routine Monitoring
Dose-related effect on circadian phase shift and amplitude in healthy volunteers

PER3 (period 3) shows robust circadian gene oscillations and correlates the most with melatonin phase (Archer 2008)
BIIB124 (SAGE-324)

Oral neuroactive steroid GABA_A PAM under investigation for the treatment of Essential Tremor

In collaboration with Sage Therapeutics
Unmet medical need in essential tremor calls for novel treatments

- Essential tremor (ET) is one of the most prevalent movement disorder; affecting an estimated 6.4 million adults in the US\(^1\)

- Activities of daily living are adversely impacted by ET\(^2,3\) contributing negatively to psychosocial well-being\(^3,4\), general anxiety\(^3\), and overall quality of life\(^3,5\)

- High unmet need: 50% of treated patients do not respond or have sub-optimal response to standard of care treatment for ET\(^5\)

- Deficits in inhibitory signaling may play a role in the pathophysiology of ET. GABA\(_A\) PAMs have the potential to enhance inhibitory activity of the GABAergic system, the major inhibitory neurotransmitter system in the brain

- BIIB124/SAGE-324 is an investigational oral neuroactive steroid GABA\(_A\) PAM with good oral bioavailability and long half-life providing flexibility in dosing

- A single dose of BIIB124/SAGE-324 reduced tremor nearly 50% in a Phase 1 open label study with ET patients

1. Crawford SO et al. Poster Presented at: 3rd Pan American Parkinson’s and Movement Disorders Congress; 2020
3. Louis ED et al. Park Relat Disord. 2015
4. Traub RE et al. Park Relat Disord. 2010
5. Louis ED. Front Neurol. 2012
BIIB124/SAGE-324 Ph2a study (KINETIC) evaluated efficacy, safety and tolerability in essential tremor

- 1:1 randomization to 60mg or placebo orally in the morning for 28 days (n=69)
- **Inclusion criteria**: 18-80 years with ET diagnosis: isolated action tremor bilateral upper limb at least 3 years duration, with or without tremors in other locations and absence of other neurological signs, and willing to discontinue ET medications
- **Primary endpoint (Efficacy)**: Change from baseline compared to placebo in the The ET Rating Assessment Scale (TETRAS)\(^1\) Performance Subscale Item 4 upper limb tremor score on Day 29

KINETIC study met its primary endpoint

BIIB124/SAGE-324 showed a statistically significant reduction from baseline in Upper Limb Tremor Score at Day 29 (Full Analysis Set)

Greater and statistically significant reductions in those with severe upper limb tremor at baseline (TETRAS Upper Limb Score ≥ 12) during treatment period (Subgroup Analysis)
KINETIC study safety and tolerability results inform design of Phase 2b dose ranging study

**Kinetic study: Key safety and tolerability findings**

- The trial evaluated treatment of BIIB124/SAGE-324 at the higher end of the predicted dose range
- Daily dose could be down-titrated to 45 mg or 30 mg if 60 mg was not well tolerated
- Down-titration of dose occurred in 62% of patients who received BIIB124/SAGE-324
- Discontinuations due to treatment emergent adverse events occurred in 27% of patients BIIB124/SAGE-324
- Adverse events were generally consistent with the safety profile observed to date

  1. Most common treatment emergent adverse events that occurred in >10% of patients in the BIIB124/SAGE-324 treatment group and at a rate at least twice as high as that of patients in the placebo group were somnolence (68%), dizziness (38%), balance disorder (15%), diplopia (12%), dysarthria (12%), gait disturbance (12%)

**Phase 2b Study Considerations**

The efficacy and safety profile observed to date support further development of BIIB124/SAGE-324 as a potential therapeutic option for patients with ET

- Ph2b dose ranging study is designed to identify a dose with the best benefit-risk profile by evaluating a wide exposure range.
- Strategies to improve tolerability include nighttime dosing and inclusion of doses lower than 60 mg

Highlights on Movement Disorders Portfolio

01 Movement Disorders Strategy and Pipeline
Growing multi-modality, multi-target approach in Movement disorders with a focus on Parkinson’s disease

02 Advances on LRRK2 Targeting Therapies for Parkinson’s Disease
BIIB122 (DNL 151) – LRRK2 Kinase Inhibitor
• Phase 1 and 1b studies support goal to improve lysosomal function and slow progression of disease.
• Program advancing into late-stage development in idiopathic PD and LRRK2 mutation carriers

BIIB094 – LRRK2 ASO
• Ongoing SAD/MAD study to evaluate the safety, tolerability, and pharmacokinetics in PD patients

BIIB118 – CK1 Inhibitor
• Program advancing for treatment of Circadian rhythm disruptions in PD

03 Novel Approach to Essential Tremor
BIIB124 (SAGE-324) – GABA_A PAM
• Ph2 study met primary endpoint (efficacy)
• Program advancing to Ph2b dose ranging study